Using the Body’s Housecleaning Mechanism to Target Undruggable Proteins

Episode Summary

Executive Summary: The interview with Chimera CEO Nello Manalfi explains targeted protein degradation (TPD) as a platform for drugging previously inaccessible disease proteins by recruiting the ubiquitin-proteasome system. He highlights KT474’s strong early clinical proof-of-concept in immunology/inflammation, strategic partnerships with Sanofi and Vertex, and Chimera’s broader plan to remain a fully integrated company advancing multiple internal programs with a well-capitalized balance sheet.

Main Topics: Targeted Protein Degradation as a Drugging Platform (Priority: 5/5): Manalfi explains how heterobifunctional degraders bind both a disease-causing protein and an E3 ligase, causing the cell to destroy the target via the ubiquitin-proteasome system. Why TPD Expands Beyond 'Undruggable' Targets (Priority: 5/5): The discussion emphasizes that many validated disease proteins are inaccessible to conventional small molecules, antibodies, or nucleic-acid therapies because of binding, location, or delivery limits; TPD broadens the set of treatable targets. How Chimera Selects and Builds a Degrader (Priority: 4/5): The company’s workflow involves identifying a disease protein, finding or discovering a ligand for it, selecting an E3 ligase expressed in the relevant tissue, identifying an E3 ligand, and then optimizing the linked molecule into a candidate drug. KT474 Clinical Proof-of-Concept in Immunology (Priority: 5/5): Chimera’s IRAC4 degrader KT474 showed strong systemic degradation and biomarker effects in a placebo-controlled phase 1 study in healthy volunteers, with no serious adverse events reported. Partnership Strategy with Sanofi and Vertex (Priority: 4/5): Manalfi frames collaborations as accelerators: Vertex helped Chimera expand into non-oncology/immunology areas, while Sanofi supports the late-stage development of KT474 in exchange for shared economics. Pipeline, Capital, and Long-Term Independence (Priority: 4/5): Chimera says it remains primarily focused on internally owned assets, with several programs advancing toward clinic and a recent financing providing runway to build a de-risked pipeline and broader platform capabilities.

Key Arguments: TPD works by recruiting the cell’s own protein disposal machinery rather than directly inhibiting a target, enabling access to many more disease-causing proteins. Only about 15% to 20% of the human proteome has been drugged; TPD could materially expand the druggable universe. The technology is not merely an alternative to small molecules; it can also compete with antibodies, RNA, CRISPR, and other modalities by reaching intracellular and systemically relevant targets. Chimera’s approach depends on selecting the right target ligand, E3 ligase, and E3 ligand in the relevant tissue to achieve effective degradation. KT474’s placebo-controlled first-in-class phase 1 study was designed to connect pharmacokinetics, protein degradation, and downstream biomarkers early, increasing confidence in later development. The company sees KT474 as a potentially best-in-class oral immunology/inflammation asset that could replace multiple cytokine-blocking biologics with one small molecule. Partnerships are strategic, not merely financial: Vertex broadened Chimera’s disease reach, and Sanofi provides scale for late-stage clinical execution and commercialization. Chimera intends to remain a fully integrated drug discovery and development company, with most programs owned internally and additional disclosures planned.

Data Points: Human proteome drugged: 15% to 20% - Manalfi said only this fraction of the ~20,000-protein proteome has been drugged. Approximate number of human proteins: 20,000 - He described the proteome as composed of about 20,000 proteins. KT474 systemic IRAC4 degradation: up to 96% - Single-dose healthy volunteer study showed near-total systemic degradation. Duration of degradation effect: up to 7 days - The degradation effect from one dose persisted for about a week. Downstream biomarker inhibition: up to 97% - Some cytokines and chemokines were inhibited by nearly complete levels in the phase 1 study. Healthy volunteers dosed: 57 - Number of healthy volunteers enrolled/dosed in the KT474 study. Sanofi profit split: 50-50 in the U.S. - Commercial economics for KT474 under the Sanofi co-development partnership. Vertex upfront payment: $70 million - Upfront value cited for the Vertex collaboration. Vertex milestones: $1 billion in milestones - Potential milestone payments for the Vertex partnership. Sanofi upfront payment: $150 million - Upfront value cited for the Sanofi collaboration. Sanofi milestones: $2 billion+ in milestones - Potential milestone payments for the Sanofi partnership. Recent financing raised: $257 million - Upsized offering completed in July. Cash on hand: about $650 million - Company stated balance sheet after the financing. Runway: into 2025 - Management said current capital would take the company into 2025. Vertex partnership programs: 6 programs - Broad collaboration with Vertex spans six programs. Disease areas in Vertex collaboration: 5 disease areas - Those programs were said to be outside oncology and immunology across five disease areas.

Pivotal Quotes: "We just bring the disease causing protein to the proteasome. That's really what we do with the technology." — Nello Manalfi: Explaining the core mechanism of targeted protein degradation. "Only about 15 to 20% of this proteome has been drugged." — Nello Manalfi: Describing the size of the unmet opportunity in drug discovery. "Rather than swapping one antibody for one oral small molecule, we're actually going for replacing a series of antibody therapies that cannot be injected in a single human together with one oral small molecule that has the power of multiple antibodies." — Nello Manalfi: Describing the strategic promise of KT474 in inflammatory disease.

Implications: TPD could open large new drug classes across oncology, immunology, and beyond, especially for proteins unreachable by other modalities. Chimera’s early human data and strong partnerships suggest growing validation for the field and a path toward oral medicines that may rival biologics in impact.